Neoleukin Therapeutics: Lead program NL-201: cytokine mimetic (neoleukin) to activate immune cells for cancer immunotherapy; first de novo protein therapeutic ever created. IND planned for 2020. Potential for best-in-class IL-2/IL-15.
Healthcare/Drug Manufacturers
Based in...
US - Pacific
Clinical Stage
Pre-Clinical Stage
Disease Space
Allergy, Autoimmune, Immuno-Oncology, Oncology
Public, USA
Market Cap
500MM - 1B
1616 Eastlake Avenue E
Suit 360
Seattle, WA 98109
United States

Company Participants at Neoleukin Investor R&D Showcase - AACR 2020 (Virtual)

  • Jonathan G. Drachman, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Top 10 Holders of Neoleukin Therapeutics, Inc

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Redmile Group LLC 17.17 4,041,211 56.29 Stakes 2020-04-02
Ecor1 Capital LLC 15.69 3,693,203 51.45 13F 2020-03-31
Baker Bros. Advisors LP 14.44 3,397,740 47.33 13F 2020-03-31
Opaleye Management, Inc. 5.95 1,400,000 19.50 13F 2020-03-31
Boxer Capital LLC 4.29 1,009,255 14.06 13F 2020-03-31
OrbiMed Advisors LLC 3.92 921,800 12.84 13F 2020-03-31
Renaissance Technologies LLC 3.60 847,092 11.80 13F 2020-03-31
Fairmount Funds Management LLC 3.44 810,073 11.28 13F 2020-03-31
Millennium Management LLC 3.20 752,941 10.49 13F 2020-03-31
Pictet Asset Management Ltd. 2.64 621,201 8.65 13F 2020-03-31
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.